QS Investors LLC Continues to Hold Position in Amphastar Pharmaceuticals, Inc. (AMPH)

QS Investors LLC maintained its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 81,569 shares of the company’s stock at the close of the 2nd quarter. QS Investors LLC owned 0.18% of Amphastar Pharmaceuticals worth $1,457,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Vanguard Group Inc. grew its position in Amphastar Pharmaceuticals by 10.8% in the 2nd quarter. Vanguard Group Inc. now owns 2,414,797 shares of the company’s stock worth $43,128,000 after purchasing an additional 235,033 shares during the period. Dimensional Fund Advisors LP grew its position in Amphastar Pharmaceuticals by 25.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,331,842 shares of the company’s stock worth $23,786,000 after purchasing an additional 270,654 shares during the period. State Street Corp grew its position in Amphastar Pharmaceuticals by 11.1% in the 1st quarter. State Street Corp now owns 1,062,439 shares of the company’s stock worth $15,406,000 after purchasing an additional 106,448 shares during the period. Teachers Advisors LLC grew its position in Amphastar Pharmaceuticals by 1.1% in the 2nd quarter. Teachers Advisors LLC now owns 549,149 shares of the company’s stock worth $9,808,000 after purchasing an additional 6,196 shares during the period. Finally, Bank of New York Mellon Corp grew its position in Amphastar Pharmaceuticals by 11.4% in the 1st quarter. Bank of New York Mellon Corp now owns 519,802 shares of the company’s stock worth $7,536,000 after purchasing an additional 53,214 shares during the period. 44.26% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals, Inc. (NASDAQ AMPH) opened at 18.70 on Wednesday. Amphastar Pharmaceuticals, Inc. has a 1-year low of $12.05 and a 1-year high of $21.75. The stock has a market cap of $863.85 million, a PE ratio of 242.86 and a beta of 1.69. The company’s 50 day moving average is $16.58 and its 200-day moving average is $16.23.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Wednesday, August 9th. The company reported $0.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.05. The company had revenue of $65.20 million for the quarter, compared to analyst estimates of $63.40 million. Amphastar Pharmaceuticals had a net margin of 1.61% and a return on equity of 2.42%. The firm’s revenue was down 4.1% on a year-over-year basis. During the same quarter last year, the business earned $0.23 earnings per share. Equities research analysts forecast that Amphastar Pharmaceuticals, Inc. will post $0.27 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals announced that its Board of Directors has initiated a stock buyback plan on Wednesday, August 9th that authorizes the company to repurchase $20.00 million in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 2.8% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

A number of research firms have commented on AMPH. Jefferies Group LLC reaffirmed a “buy” rating and issued a $19.00 target price (down previously from $20.00) on shares of Amphastar Pharmaceuticals in a research report on Friday, August 11th. Piper Jaffray Companies set a $19.00 target price on shares of Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Needham & Company LLC lifted their target price on shares of Amphastar Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, September 27th. Finally, ValuEngine downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Three research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. Amphastar Pharmaceuticals currently has an average rating of “Hold” and an average price target of $20.17.

ILLEGAL ACTIVITY NOTICE: “QS Investors LLC Continues to Hold Position in Amphastar Pharmaceuticals, Inc. (AMPH)” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://sportsperspectives.com/2017/10/11/qs-investors-llc-continues-to-hold-position-in-amphastar-pharmaceuticals-inc-amph.html.

In other news, EVP Diane G. Gerst sold 8,444 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $18.87, for a total value of $159,338.28. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $14.81, for a total transaction of $148,100.00. Following the completion of the sale, the director now owns 33,844 shares in the company, valued at approximately $501,229.64. The disclosure for this sale can be found here. In the last quarter, insiders sold 126,380 shares of company stock worth $2,268,933. Company insiders own 11.10% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply